Next Article in Journal
Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors
Previous Article in Journal
Hepatoprotective Effect of Aqueous Extract from the Seeds of Orychophragmus violaceus against Liver Injury in Mice and HepG2 Cells
Previous Article in Special Issue
Hormetic Response to Low-Dose Radiation: Focus on the Immune System and Its Clinical Implications
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(6), 1273; doi:10.3390/ijms18061273

Hormesis and Defense of Infectious Disease

1
Department of Anesthesiology and Intensive Care Medicine, University Hospital Jena, Jena 07747, Germany
2
Center for Infectious Diseases and Infection Control, University Hospital Jena, Jena 07747, Germany
3
Center for Sepsis Control and Care, University Hospital Jena, Jena 07747, Germany
4
Institute of Molecular Cell Biology, Center for Molecular Biomedicine (CMB), University Hospital Jena, Jena 07745, Germany
5
Fritz Lipmann Institute, Leibniz Institute on Aging, Jena 07745, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Guido R. M. M. Haenen
Received: 18 April 2017 / Revised: 16 May 2017 / Accepted: 20 May 2017 / Published: 15 June 2017
(This article belongs to the Special Issue Hormesis and Transhormesis in Toxicology and Risk Assessment)
View Full-Text   |   Download PDF [712 KB, uploaded 15 June 2017]   |  

Abstract

Infectious diseases are a global health burden and remain associated with high social and economic impact. Treatment of affected patients largely relies on antimicrobial agents that act by directly targeting microbial replication. Despite the utility of host specific therapies having been assessed in previous clinical trials, such as targeting the immune response via modulating the cytokine release in sepsis, results have largely been frustrating and did not lead to the introduction of new therapeutic tools. In this article, we will discuss current evidence arguing that, by applying the concept of hormesis, already approved pharmacological agents could be used therapeutically to increase survival of patients with infectious disease via improving disease tolerance, a defense mechanism that decreases the extent of infection-associated tissue damage without directly targeting pathogenic microorganisms. View Full-Text
Keywords: tissue damage; tolerance; hormesis; sepsis; DNA damage tissue damage; tolerance; hormesis; sepsis; DNA damage
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Weis, S.; Rubio, I.; Ludwig, K.; Weigel, C.; Jentho, E. Hormesis and Defense of Infectious Disease. Int. J. Mol. Sci. 2017, 18, 1273.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top